“BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis As Assessed by the Static Physician’s Global Assessment (sPGA) Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s29, https://doi.org/10.25251/skin.4.supp.29.